The Oncology Institute, Inc. TOI Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Other Operating Income by Business | ||||||
| Clinical trials & other | $813K-54.2% | $772K-61.3% | $474K-69.6% | $1.22M-10.6% | $1.77M-15.0% | |
| Patient services | $4.25M-5.9% | $5.76M+146% | $4.17M+24.2% | $3.26M-31.0% | $4.52M+162% | |
| Specialty pharmacy | $16.8M+78.7% | —— | —— | —— | $9.4M+31.6% | |
| Total segment amortization by Business | ||||||
| Clinical trials & other | $0-100% | $0-100% | $0-100% | $55K0.0% | $55K0.0% | |
| Patient services | $718K0.0% | $717K-50.1% | $717K-0.1% | $718K-0.1% | $718K0.0% | |
| Total Assets by Business | ||||||
| Clinical trials & other | $6.04M-24.5% | $5.44M-31.8% | $4.03M-52.1% | $4.78M-52.3% | $8M-19.1% | |
| Patient services | $83.12M+26.4% | $74.66M+9.1% | $74.09M+2.1% | $70.03M-1.0% | $65.75M-15.7% | |
| Specialty pharmacy | $29.14M— | $16.68M+15.6% | —— | —— | —— | |
| Depreciation expense by Business | ||||||
| Clinical trials & other | $0-100% | $8K+300% | $0— | $0-100% | $2K— | |
| Patient services | $737K-2.4% | $660K-4.8% | $737K+31.8% | $767K+53.4% | $755K+46.6% | |
| Specialty pharmacy | $3K-90.6% | —— | —— | —— | $32K+3.2% | |
| Total operating revenue by Product | ||||||
| Capitated revenue | $26.93M+53.9% | $23.57M+34.6% | $20.57M+38.9% | $18.84M+0.8% | $17.5M-1.0% | |
| Clinical trials & other | $813K-60.2% | $705K-71.4% | $474K-75.6% | $1.34M-20.2% | $2.05M-19.3% | |
| FFS revenue | $32.16M-9.6% | $36.27M+10.9% | $39.62M+13.4% | $37.05M+9.7% | $35.57M+2.3% | |
| Patient services | $59.09M+11.3% | $59.84M+19.2% | $60.2M+21.0% | $55.89M+6.5% | $53.07M+1.2% | |
| Specialty Pharmacy | $87.54M+77.6% | —— | —— | —— | $49.29M+9.6% | |
| Total Assets by Product | ||||||
| Capitated accounts receivable | $1.57M-59.6% | $3.21M-13.0% | $2.9M— | $2.27M— | $3.88M— | |
| FFS accounts receivable | $33.64M+17.6% | $35.38M+33.3% | $35.34M— | $31.9M— | $28.59M— | |
| IV drug inventory | $13.55M+108% | $8.08M+23.2% | $7.61M— | $7.29M— | $6.52M— | |
| Oral drug accounts receivable | $10M+31.1% | $7.46M+17.0% | $8.85M— | $11.26M— | $7.62M— | |
| Oral drug inventory | $10.75M+85.6% | $8.8M+153% | $11.27M— | $8.5M— | $5.79M— | |
| Other assets | $42.77M+42.1% | $28.42M-21.6% | $35.35M— | $33.75M— | $30.09M— | |
| Direct costs by Product | ||||||
| Clinician salaries and benefits | $15.34M+9.0% | —— | $14.77M-1.1% | —— | $14.07M— | |
| Intravenous (IV) drug costs | $29.77M-5.2% | —— | $36.82M+28.1% | —— | $31.41M— | |
| Medical supplies and other | $8.28M+420% | —— | $2.98M+109% | —— | $1.59M— | |
| Number of lease modifications by Geography | ||||||
| CALIFORNIA | 1— | —— | —— | —— | —— | |
| FLORIDA | 4— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does The Oncology Institute, Inc. break its business down?
- The Oncology Institute, Inc. (TOI) reports other operating income by business across 3 parts — Clinical trials & other, Patient services and Specialty pharmacy. Each is extracted from the segment footnotes and tracked over time.
- Where does The Oncology Institute, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in The Oncology Institute, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
